Drug induced sensory neuropathies

  • E. Sluga
  • M. Graf
  • T. Paternostro-Sluga
  • W. Grisold
  • B. Mamoli
Conference paper


Drug induced neuropathies are mostly sensory-motor with a considerable number of predominantly sensory type (Fig. 1). Among the causative agents for sensory neuropathies (SN) cytostatics are at the top, followed by very differently acting and used substances like for instance almitrine, a bronchodilatator, the antiretroviral agent dideoxycytidine (dd) or vitamin B 6-abuse (Fig. 1). The only chiefly motor neuropathy among the cytostatics is caused by the recently used mab Ricin A, a new immunotoxin inducing demyelination (Fig. 1).


Peripheral Neuropathy Sensory Neuropathy Sjogren Syndrome Sural Nerve Biopsy Dorsal Root Ganglion Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.



  1. 1.
    Mollman JE, Glover DJ, Hogan M, Furman RE (1988) Cisplatin neuropathy. Risk factors, prognosis and protection by WR 2721. Cancer 61: 2912–2195CrossRefGoogle Scholar
  2. 2.
    Riggs JE, Ashrof M, Snyder RD, Gutmann L (1988) Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 23: 92–94PubMedCrossRefGoogle Scholar
  3. 3.
    Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938PubMedCrossRefGoogle Scholar


  1. 4.
    Lipton RB, Apfel SC, Dutcher JP et al (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39: 368–373PubMedCrossRefGoogle Scholar


  1. 5.
    Borgeat A, Muralt de B, Stalder M (1986) Peripheral neuropathy associated with high-dose ara-C-therapy. Cancer 58: 852–854PubMedCrossRefGoogle Scholar
  2. 6.
    Lorenzoni E, Müller R, Fauler J (1987) Polyneuropathien nach Vidarabinphosphat. Aktuelle Neurologie 14: 53–56CrossRefGoogle Scholar
  3. 7.
    Powell BL, Capizzi RL, Lyerly ES, Cooper MR (1986) Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin and asparaginase. Consolidation for acute non-lymphocytic leucaemia. J Clin Oncology 4: 95–97Google Scholar

Vinca Alkaloide

  1. 8.
    Hermet R, Vernay D, Lopitaux R et al (1990) Neuropathie aigue a la vincristine. Therapie 45: 47–52Google Scholar
  2. 9.
    Sandler SG, Tobin W, Henderson ES (1969) Vincristine-induced neuropathy. Neurology 19: 370–371Google Scholar

Ricin A

  1. 10.
    Gould BJ, Borowitz MJ, Groves ES et al (1989) Phase I study of an anti-breast cancer immunotoxin (monoclonal ab — recombinant Ricin A-chain) by continous infusion: Report of a targeted toxic effect not predicted by animal studies. J Nat Cancer Inst 81:775–781PubMedCrossRefGoogle Scholar


  1. 11.
    Blondel M, Arnott G, Defoort S et al (1986) 11 patients with peripheral neuropathy related to almitrine therapy. Visual impairement in one. Rev Neurol 142: 683–688PubMedGoogle Scholar
  2. 12.
    Gherardi R, Baudrimont M, Gray F, Louores F (1987) Almitrine neuropathy. A nerve biopsy study of 8 cases. Acta Neuropathol 73: 202–208PubMedCrossRefGoogle Scholar
  3. 13.
    Gherardi R et al (1985) Peripheral neuropathy in patients treated with almitrine dimesylate. Lancet: 1247–1249Google Scholar


  1. 14.
    Accetta GS, Fitzmorris AO, Wettingfeld RF (1954) Toxicity of methimazole (tapazole). J Am Med Assoc 155: 254–254CrossRefGoogle Scholar
  2. 15.
    Leger JM, Dancea S, Brunet P, Hauw JJ (1984) Polyneuropathie au cours d’un traitement par le carbimazole. Rev Neurol 140: 652–656PubMedGoogle Scholar
  3. 16.
    Mc Gregor A et al (1980) Carbimazole and autoantibody synthesis in Hashimoto’s thyreoiditis. Br Med J 281: 961–968CrossRefGoogle Scholar
  4. 17.
    Mikol F, Bouchareine A, Fraisse F et al (1979) Polyradiculonevrite a rechute. Role possible du Carbimazole. Rev Neurol 135: 835–837PubMedGoogle Scholar
  5. 18.
    Mikol F, Simon F, Falcy M (1982) Syndrome de Gougerot-Sjögren et polyradiculonevrite au Carbimazole. Rev Neurol 138: 259–262PubMedGoogle Scholar


  1. 19.
    Dubinski RM, Yarchoan R, Dalakas M, Broder S (1989) Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerv 12: 856–860CrossRefGoogle Scholar
  2. 20.
    Schaumburg HH, Arezzo J, Berger A (1990) Dideoxycytidine (ddC)-neuropathy in human immundeficiency virus infections: a report of 52 patients. Neurology 40: 428Google Scholar


  1. 21.
    Dubois A, Raffanel C, Pignodel C et al (1983) Acute cerebellar syndrome with sensory neuropathy in a patient treated with metronidazole. Presse medicale 12 (24): 1547–1548Google Scholar
  2. 22.
    Duffy LF, Daum F, Fisher SE et al (1985) Peripheral neuropathy in Crohn’s disease patients treated with metronidazole. Gastroenterology 88: 681–684PubMedGoogle Scholar


  1. 23.
    Kogelnik HD, Meyer HJ, Jentsch K et al (1978) Further clinical experiences of a phase I study with hypoxic cell radiosensitizer. Br J Cancer 37 [Suppl III]: 281Google Scholar
  2. 24.
    Mamoli B, Wessely P, Kogelnik HD et al (1979) Electroneurographic investigations of misonidazole polyneuropathy. Eur Neurol 18: 405–414PubMedCrossRefGoogle Scholar


  1. 25.
    Filley CM, Graff-Rudford NR, Lacy JR et al (1982) Neurological manifestations of podophyllin toxicity. Neurology 32: 308–311PubMedCrossRefGoogle Scholar
  2. 26.
    Mahoney SO, Keohane C, Jacobs J et al (1990) Neuropathy due to podophyllin intoxication. J Neurol 237: 110–112CrossRefGoogle Scholar


  1. 27.
    Albin RL, Albus JW, Greenburg HS et al (1987) Acute sensory neuropathy — neuropathy from pyridoxine overdose. Neurology 37: 1729–1732PubMedCrossRefGoogle Scholar
  2. 28.
    Dalton K, Dalton JT (1987) Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 76: 8–11PubMedCrossRefGoogle Scholar
  3. 29.
    Schaumburg HH, Kaplan J, Windebank E et al (1983) Sensory neuropathy from pyridoxin abuse: a new megavitamine syndrome. N Engl J Med 309: 445–448PubMedCrossRefGoogle Scholar


  1. 30.
    Aronson IK, Yu R, West DP et al (1984) Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 120: 1466–1470PubMedCrossRefGoogle Scholar
  2. 31.
    Chapon F, Lechevalier B, Da Silva DC et al (1985) Thalidomide induced neuropathy. Rev Neurol 141: 719–728PubMedGoogle Scholar
  3. 32.
    Wulff CH, Hoyer H, Asboe-Hanser G, Brodthagen H (1985) Development of polyneuropathy during thalidomide therapy. Br J Dermatol 112: 475–480PubMedCrossRefGoogle Scholar

Gold (Aureo-thio-glucose/-malate)

  1. 33.
    Fam AG, Gordon DA, Sarzoki J et al (1984) Neurological complications with gold therapy for rheumatoid arthritis. J Rheumatol 11: 700–706PubMedGoogle Scholar
  2. 34.
    Katrak SM, Pollock M, O’Brien C et al (1980) Clinical and morphological features of gold neuropathy. Brain 103: 671–693PubMedCrossRefGoogle Scholar


  1. 35.
    Borrett D, Ashby P, Bilbao J, Cavlen P (1985) Reversible, late-onset disulfiram-induced neuropathy and encephalopathy. Ann Neurol 17: 396–399PubMedCrossRefGoogle Scholar
  2. 36.
    Mokri B, Onishi A, Dyck PJ (1981) Disulfiram neuropathy. Neurol 31: 730–735CrossRefGoogle Scholar
  3. 37.
    Schütze HJ, Busse O, Vuia O (1983) Polyneuropathie nach Disulfiram-Intoxikation. Arch Psych Nervenkrkh 233: 1–8CrossRefGoogle Scholar


  1. 38.
    Said G (1978) Perhexilen neuropathy. A clinico-pathological study. Ann Neurol 3: 259PubMedCrossRefGoogle Scholar


  1. 39.
    Lovelace RE, Horwitz SJ (1968) Peripheral neuropathy in long-term diphenylhydantoin therapy. Arch Neurol 18: 69–77PubMedCrossRefGoogle Scholar
  2. 40.
    Swift ThR, Gross JA, Ward Ch, Crout B (1981) Peripheral neuropathy in epileptic patients. Neurology 31: 826–831PubMedCrossRefGoogle Scholar


  1. 41.
    Lemaire JF, Autret A, Bizien K et al (1982) Amiodaron neuropathy: Further arguments for human drug-induced neurolipidosis. Eur Neurol 2: 65–68CrossRefGoogle Scholar
  2. 42.
    Palakurthy DP, Iyer V, Meckle RJ (1987) Unusual neurotoxicity associated with amiodarone therapy. Arch Int Med 147: 881–884CrossRefGoogle Scholar
  3. 43.
    Pellisier JF, Pouget J, Cros D et al (1984) Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study. J Neurol Sci 63: 251–266CrossRefGoogle Scholar


  1. 44.
    Ahrens EM, Meckler RJ, Callen JP (1986) Dapsone-induced peripheral neuropathy. Int J Dermatology 25: 314–316CrossRefGoogle Scholar
  2. 45.
    Daneshmend TK (1984) The neurotoxicity of dapsone. Acute drug reactions and acute poisoning. Review 3: 43–58Google Scholar
  3. 46.
    Sebille A, Cordoliani G, Raffalli MJ et al (1987) Dapsone induced neuropathy compounds Hansen’s disease nerve damage. Int J Leprosy 55: 16–22Google Scholar


  1. 47.
    Gold BC, Griffin JW, Price DL (1985) Slow axonal transport in acrylamid neuropathy: different abnormalities produced by single dose and continous administration. J Neurosci 5:1755–1768PubMedGoogle Scholar
  2. 48.
    Gold BC, Hallek MM (1989) Axonal degeneration and axonal caliber alterations following combined IDPN and acrylamid administration. J Neuropath Exp Neurol 48: 653–668PubMedCrossRefGoogle Scholar


  1. 49.
    Kurihara K, Kita K et al (1986) N-hexane neuropathy due to sniffing bond G 10. Clinical and elmi findings. Brain and Nerve 38: 1011–1017Google Scholar
  2. 50.
    Sahenk Z, Mendell JR (1981) Acrylamide and 2.5-hexanedione neuropathies: abnormal bidirectional transport rate in distal axones. Brain Res 219: 397–405PubMedCrossRefGoogle Scholar


  1. 51.
    Le Witt P (1980) The neurotoxicity of the rat poison vacor. N Engl J Med 302: 73–77CrossRefGoogle Scholar
  2. 52.
    Watson DF, Griffin JW (1987) Vacor neuropathy: ultrastructural and axonal transport studies. J Neuropathol Exp Neurol 46: 96–108PubMedCrossRefGoogle Scholar


  1. 53.
    Inoué N, Fujishiro K, Mori K, Matsuoka M (1988) Triorthocresyl-phosphate poisoning-a review of human cases. J VOEH 10: 433–442Google Scholar


  1. 54.
    Griffin JW, Falmestock KE, Price DL, Hoffman PN (1983) Microtubule-neurofilament seggregation produced by β-β′-IDPN: Evidence for the association of fast axonal transport with microtubules. J Neurol Sci 3: 557–566Google Scholar


  1. 55.
    Cho ES, Spencer PS, Jortner BS, Schaumburg HH (1980) A single intravenous injection of doxorubicin (adriamycin) induces sensory neuropathy in rats. Neurotoxicology 1: 583–591Google Scholar


  1. 56.
    Hiura A, Ishizuka H (1989) Changes in features of degenerating primary sensory neurons with time after capsaicin treatment. Acta Neuropathol 78: 35–46PubMedCrossRefGoogle Scholar
  2. 57.
    Taylor DCM, Pirau FK, Szolcsanyi J (1985) Capsaicin induced inhibition of axoplasmic transport is prevented by NGF. Cell Tissue Res 260: 569–573CrossRefGoogle Scholar


  1. 58.
    La Rocca RV, Meer J, Gilliatt RW et al (1990) Suramin-induced polyneuropathy. Neurology 40:954–960PubMedCrossRefGoogle Scholar


  1. 59.
    Schmidt RE, Summerfield AL, Hickey WF (1990) Ultrastructural and immunohistologic characterization of guanethidine-induced destruction of peripheral sympathetic neurons. J Neuropathol Exp Neurol 49: 150–167PubMedCrossRefGoogle Scholar


  1. 60.
    Dalakas W (1986) Chronic idiopathic ataxic neuropathy. Ann Neurol 19: 545–554PubMedCrossRefGoogle Scholar
  2. 61.
    Griffin JW, Cornblath DR, Alexander E et al (1990) Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren’s syndrome. Ann Neurol 27: 304–315PubMedCrossRefGoogle Scholar
  3. 62.
    Griffin JW, Watson DF (1988) Axonal transport in neurological desease. Ann Neurol 23: 3–13PubMedCrossRefGoogle Scholar
  4. 63.
    Schaumburg HH, Spencer PS (1979) Toxic neuropathies. Neurology 29: 429–431PubMedCrossRefGoogle Scholar
  5. 64.
    Snider WD, Johnson EM (1989) Neurotrophic molecules. Ann Neurol 26: 489–506PubMedCrossRefGoogle Scholar
  6. 65.
    Spencer PS, Schaumburg HH (1978) Pathobiology of neurotoxic axonal degeneration. In: Waxman SG (ed) Physiology and pathobiology of axons. Raven, New York, pp 265–282Google Scholar
  7. 66.
    Sterman AB, Schaumburg HH, Asbury AK (1980) The acute sensory neuronopathy syndrome. A distinct clinical entity. Ann Neurol 7: 354–358PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1995

Authors and Affiliations

  • E. Sluga
    • 1
  • M. Graf
    • 1
  • T. Paternostro-Sluga
    • 2
  • W. Grisold
    • 3
  • B. Mamoli
    • 4
  1. 1.Department of NeurologyWilhelminenspitalViennaAustria
  2. 2.Electrophysiological Lab, Department of NeurologyKrankenhaus LainzViennaAustria
  3. 3.Department of NeurologyFranz Josef SpitalViennaAustria
  4. 4.Department BNeurological Hospital RosenhügelViennaAustria

Personalised recommendations